LOS ANGELES, May 17, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today highlighted
that clinical data showing the lack of cardiac toxicity associated
with treatment with partner NantCell's aldoxorubicin will be
featured in a poster presentation at the American Society of
Clinical Oncology (ASCO) 2018 Annual Meeting, taking place
June 1-5, 2018 in Chicago. The data were obtained from two
clinical trials of aldoxorubicin, a rationally-engineered cytotoxic
which employs a linker bound to albumin to deliver doxorubicin
directly into the tumor.
Fifty-two patients enrolled in a Phase 1/2 study of
aldoxorubicin and ifosfamide/mesna, and a Phase 3 study using
aldoxorubicin alone were treated for at least 6 cycles with
aldoxorubicin at either 250 mg/m2 or 350
mg/m2 per dose intravenously every 3 weeks. Cardiac
function was evaluated by echocardiogram at regular intervals every
two cycles until the end of treatment and every six months
following completion of the treatment. The cumulative aldoxorubicin
dose ranged from 1000 to 7500 mg/m2. Results from
this study show these cumulative doses did not significantly change
echo cardiogram assessed cardiac function.
"While doxorubicin, either alone or in combination with
ifosfamide, is still considered standard therapy for sarcomas, this
new data adds to the growing body of evidence showing that
aldoxorubicin, either alone or in combination with ifosfamide, may
be able to improve antitumor activity without typical doxorubicin
associated cardiac toxicity," said Sant
Chawla M.D., F.R.A.C.P., Director of the Sarcoma Oncology
Center in Santa Monica, Principal
Investigator for both studies, and co-author of the abstract. "We
are pleased to present such important data showing aldoxorubicin's
lack of cardiotoxicity up to the doxorubicin equivalent dose of
7500 mg/m2, and look forward to its further clinical
development."
CytRx out-licensed global development, manufacturing, and
commercialization rights for aldoxorubicin to NantCell, Inc., a
private subsidiary of NantWorks, LLC, in July 2017.
Details for the poster presentation at ASCO 2018:
Title: Lack of cardiac toxicity in patients treated with
Aldoxorubicin with Doxorubicin equivalent doses beyond
1000mg/m2
Lead Author: Dr. Kamalesh Kumar
Sankhala, of the Sarcoma Oncology Center in Santa Monica
Abstract #: 11585
Poster Session Title: Sarcoma
Date and Time: Saturday, June 2, 2018, 8:00 –
11:30 AM CT
About ASCO
The American Society of Clinical Oncology Annual Meeting is
one of the largest and most influential conferences in the field.
It is an international gathering that brings together more than
40,000 oncology professionals, thought leaders, patient advocates
and the general public to present cutting-edge treatment
modalities, discuss new therapies, and debate ongoing
controversies. The 2018 meeting will take place
in Chicago, June 1 through June 5. ASCO provides
conference attendees with a variety of perspectives on treatment
through debates, tumor boards, presentations of abstracts, and Meet
the Professor sessions. New in 2018, the conference will
feature ASCO Voices, a thought-provoking one-hour
session devoted to the presentation of 7-minute long talks that
convey the speaker's ideas and passion, without incorporating
slides, data or figures of any kind.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical
Company specializing in research and clinical development of novel
anti-cancer drug candidates that employ linker technologies to
enhance the accumulation and release of drug at the
tumor. CytRx is rapidly expanding its pipeline of
ultra-high potency oncology candidates at its laboratory facilities
in Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker
technology for the development of a new class of potential
breakthrough anti-cancer therapies.
Aldoxorubicin, CytRx's most advanced drug conjugate, is
an improved version of the widely used anti-cancer drug doxorubicin
and has been out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to
obtain regulatory approval for its products that use aldoxorubicin;
the ability of NantCell, Inc., to manufacture and
commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; our ability to develop new
ultra-high potency drug candidates based on our LADR™ technology
platform; and other risks and uncertainties described in the most
recent annual and quarterly reports filed by CytRx with
the Securities and Exchange Commission and current
reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements
are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-nantcell-incs-aldoxorubicin-clinical-data-to-be-presented-at-the-american-society-of-clinical-oncology-2018-annual-meeting-300650008.html
SOURCE CytRx Corporation